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Abstract 
Background: Patient education is integral to the treatment and care of patients with rheumatoid arthritis. Change is 
taking place in the organisation of healthcare systems because of a demographic shift towards ageing populations, 
an increasing use of technology and advancements in digital technologies, allowing for new interventions. This study 
will aim to evaluate the effectiveness of a newly developed e‑learning patient education programme based on self‑
management that targets patients with rheumatoid arthritis.
Methods: A pragmatic multi‑centre randomised controlled trial is planned. We intend to recruit approximately 200 
patients with a new diagnosis (< 3 months) of rheumatoid arthritis. Participants will be randomised 1:1 to web‑based 
patient education delivered through an e‑learning programme at home or standard face‑to‑face patient education 
provided at the hospital. The primary outcome is self‑efficacy. Secondary outcomes are improved knowledge of 
rheumatoid arthritis, adherence to medication, health literacy level and quality of life. Outcomes will be measured at 
baseline and follow‑up occurring 1, 3, 6 and 12 months after enrolment. Furthermore, data on healthcare utilisation 
and utilisation of the e‑learning programme will be assessed at the 12‑month follow‑up. Statistical analysis, including 
differences between groups, will be evaluated using the chi‑square and Kruskal–Wallis tests. Statistical analysis will fol‑
low the intention‑to‑treat principle, and analysis of variance will be used to evaluate the within‑ and between‑groups 
differences testing the hypothesis of the ‘superiority’ of web‑based patient education over standard face‑to‑face 
education provided at the hospital. Per protocol analysis will be used to assess the impact of missing data. Enrolment 
started in February 2021 and will end in June 2022.
Discussion: The study is expected to contribute to the evidence on the effectiveness of web‑based patient educa‑
tion within rheumatic diseases. If the e‑learning programme is effective, it will be incorporated into existing services 
to improve the self‑management of patients with rheumatoid arthritis. Further, this mode of providing patient 
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Background
Patient education with the aim of supporting patients to 
self-manage their disease is considered an important part 
of the treatment and care offered to patients with rheu-
matoid arthritis (RA) [1–3]. RA is a chronic autoimmune 
inflammatory disease affecting the joints and organs 
[4, 5]; it has a worldwide prevalence of approximately 5 
per 1000 people [6]. Pain and swelling of the joints and 
fatigue are common symptoms that may reduce physical 
function and affect quality of life (QoL) [6]. Furthermore, 
a report from the World Health Organization (WHO) 
highlights the strong relationships between painful mus-
culoskeletal conditions and reduced physical activity, 
functional capacity and well-being [7]. Patient education 
enables patients to self-manage their illness and cope 
with their condition, thereby maintaining a higher QoL 
[1, 3].
The management and treatment of RA has improved 
significantly over the last 2 decades [2, 6]. Despite rising 
prevalence because of demographic development, i.e. the 
ageing population [7–10], the prognosis and outcomes 
of patients with RA have generally improved. However, 
this places new demands on the healthcare system and 
calls for alternative solutions to conventional models 
of care. The present advancements in digital technolo-
gies allow for the delivery of new interventions, includ-
ing patient education delivered in combinations of text, 
images, audio, video, animations and interactive features 
to enhance access and understanding [11].
Nurses play an important role in supporting patients 
to participate actively in the treatment of their chronic 
conditions and in achieving self-management skills [12]. 
The Stanford Arthritis Self-Management Programme 
(ASMP) [13–15] is built on social cognitive theory [16] 
and is implemented for many chronic diseases [13–15]. 
According to the ASMP, self-management means hav-
ing or being able to acquire the skills and resources nec-
essary to best accommodate the chronic disease and its 
consequences [16]. Self-efficacy, that is, the confidence 
a person feels about performing a particular activity, is 
considered a pre-condition of self-management [17]. It 
has been shown that self-management education can lead 
to behaviour changes for patients with chronic diseases, 
and thus, improve outcomes in the forms of increased 
self-efficacy and treatment adherence, higher self-rated 
health, increased activity and decreased depression and 
anxiety [18].
Educational needs vary among individuals and can 
change throughout the course of a disease [1]. For this 
reason, it is recommended for patient education on RA 
to be individually tailored and cover several aspects, for 
example, knowledge of the disease and treatment, non-
pharmacological treatment, pain control, self-help meth-
ods, activity regulation, physical exercise and emotional 
issues [1]. At the minimum, patient education must be 
offered at the time of diagnosis and when pharmacologi-
cal treatment changes [1]. Patient education can be pro-
vided face-to-face or on the web, supplemented by phone 
calls and written or multimedia material [1].
Only a few randomised controlled trials (RCTs) have 
been conducted in the area of web-based patient edu-
cation targeting people with RA. However, within both 
rheumatology (RA, fibromyalgia, low back pain) and 
other chronic diseases, the evidence points towards 
improvement of self-efficacy, knowledge, psychological 
distress and QoL in studies evaluating web-based self-
management tools [19–23].
Evidence shows that so-called ‘entertainment educa-
tion’ can improve self-efficacy by merging educational 
content with entertainment messages to increase knowl-
edge, create favourable attitudes and change behaviour 
[24–27]. The main elements are narratives, stories and 
messages, combined with facts disseminated in an enter-
taining manner [24, 25].
As we write this protocol, approximately 90% of fami-
lies in Europe have access to the internet [28]. However, 
there are variations in computer skills [28], and the use 
of health-related digital sources is lower among people 
with low educational levels [29]. A systematic review 
of 34 studies looking at the meaning of health literacy 
identified three key elements: (1) knowledge of health, 
healthcare and health systems; (2) processing and using 
information in various formats in relation to health 
and health care; and (3) the ability to maintain health 
through self-management and working in partnerships 
with health providers [30]. Health literacy is the degree 
education may impact the organisation of health care for both rheumatic diseases and other chronic diseases by 
offering different modes of delivering patient education based on the needs and preferences of patients.
Trial registration: ClinicalTrials.gov identifier NCT04669340. Registered on November 27, 2020. https:// www. clini caltr 
ials. gov/ ct2/ show/ NCT04 669340? term=e‑ learn ing& cond= Rheum atoid+ Arthr itis& draw= 2& rank=1. See Additional 
file 1 for detailed information on the dataset according to the World Health Organization Trial Registration Data Set.
Keywords: Rheumatoid arthritis, Patient education, Web‑based patient education, e‑learning, Self‑management, 
Randomised controlled trial
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to which individuals have the capacity to obtain, process 
and understand the basic health information and ser-
vices needed to make appropriate health decisions [31]. 
We presume that health literacy skills may vary; there-
fore, health literacy principles must be considered when 
designing modern health information and services, as 
this may strengthen the usability for a broader audience 
[32].
Patient education based on digital technology may 
have several advantages. First, a web-based patient edu-
cation programme can be accessed repeatedly, which 
can be favourable to the comprehension of the provided 
information and as needs changes; furthermore, repeti-
tion of a performance increases a person’s self-efficacy 
[17]. Second, since both auditory and visual channels are 
used, the integration of words and images in web-based 
programmes can promote deeper understanding and 
learning [33]. Moreover, digital tools provide flexibility 
and accessibility [11], and it may be beneficial for patients 
to access the programme at their time of convenience in 
familiar surroundings and possibly with relatives. Pos-
sible disadvantages of web-based patient education may 
be related to the absence of face-to-face contact with 
healthcare professionals who can facilitate an individual 
approach through a conversation. Moreover, health-
care professionals may encourage and motivate patients 
through relationships and face-to-face communication.
We have developed an e-learning programme, target-
ing patients with RA. The development draws on ele-
ments of the cognitive theory of multimedia learning 
[33], entertainment education [24, 25] and didactics to 
accommodate different ways of learning and levels of 
health literacy. It is divided into three learning modules: 
(1) knowledge of RA, the typical disease course, prog-
nosis and medication; (2) additional information on RA, 
treatment possibilities and examinations; and (3) daily 
living with RA, for example, coping with emotions, pain, 
fatigue, activity, work and education. The programme 
offers a combination of animations, videos with patients 
and health professionals, graphics, podcasts, written text, 
speech and tests.
This paper reports the study protocol for an RCT 
evaluating the effectiveness of the described e-learning 
programme in improving patients’ self-management of 
RA. We hypothesise that the e-learning patient educa-
tion programme will be superior to standard face-to-face 
patient education in improving the primary outcome, 
which is self-efficacy.
Methods/design
The WebRA study is a pragmatic multi-centre RCT with 
two arms. In the study, participants will be randomised 
1:1 to either the intervention group, with web-based 
patient education delivered through an e-learning pro-
gramme provided at home, or control group, with 
standard face-to-face patient education provided at the 
outpatient clinic by a nurse. Enrolment started in Febru-
ary 2021 and is expected to be completed in June 2022. 
Follow-up and assessment of outcomes will be carried 
out 1, 3, 6 and 12 months after enrolment. Figure 1 pre-
sents the steps from enrolment to follow-up. This RCT 
will follow the Consolidated Standards of Reporting Tri-
als (CONSORT) 2010 guideline [34] and the protocol 
follows the SPIRIT (Standard Protocol Items: Recom-
mendations for Interventional Trials) guidelines and 
checklist [35].
Study population and setting
Patients will be considered eligible for the study if they 
have been diagnosed with RA according to the Ameri-
can College of Rheumatology/European League Against 
Rheumatism 2010 (ACR/EULAR 2010) criteria [4] 
within the past 3  months. Patients will receive written 
and verbal information about the study and their rights 
as participants in a clinical trial by a study nurse and will 
be included if they fulfil the inclusion criteria and have 
signed informed consent. The study will be carried out 
at five rheumatology clinics in Denmark, which are as 
follows: Aarhus University Hospital, Aalborg University 
Hospital, Odense University Hospital, Randers Regional 
Hospital and Horsens Regional Hospital. Patients will be 
recruited in connection with an outpatient visit.
Inclusion and exclusion criteria
The inclusion criteria are as follows:
• RA diagnosed according to the ACR/EULAR 2010 
criteria within the past 3 months.
• Adults ≥ 18 years old.
• Ability to speak, read and understand Danish.
• Access to the internet at home.
• Access to e-Boks (secure online mailbox in the Dan-
ish public sector) and a private e-mail address.
Patients will be excluded if they already participated in 
formalised patient education when diagnosed with RA or 
if they withdraw consent.
Medical treatment and standard care
According to guidelines, patients with RA are 
treated with disease-modifying anti-rheumatic drugs 
(DMARDs) based on disease activity, safety issues and 
individual patient factors [36]. Methotrexate (MTX) is 
the first drug of choice and will be escalated until treat-
to-target, that is, remission or low disease activity [36]. 
Patient information on treatment, including treatment 
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options, side effects and risk factors, should be pro-
vided throughout the course of disease and at medical 
treatment change [1, 2]. Thus, participants will receive 
written and verbal information about initiated medical 
treatment throughout the study period. Furthermore, 
information on symptoms and disease signs will be 
given to ensure appropriate reactions in the case of a 
disease flare or an infection.
REDCap—Research Electronic Data Capture tool
Study data are collected and managed using Research 
Electronic Data Capture (REDCap) hosted at Aarhus 
University [37, 38]. REDCap is a secure, web-based 
software platform designed to support data capture for 
research studies [37, 38]. Thus, all data collected from 
the medical records, interviews with patients and ques-
tionnaires related to the outcomes of the study will be 
collected, administered, stored and managed through 
REDCap.
Enrolment and randomisation
A study nurse will enrol patients in the study at a sched-
uled visit in the outpatient clinic or by phone. At enrol-
ment, the study nurse will obtain demographic data 
through patient interviews and baseline data on diagno-
sis and medical treatment. Disease activity by the time 
of diagnosis will be obtained via the medical records 
(Table  1). Next, participants will be randomised using 
REDCap. The randomisation allocation tables in REDCap 
were performed by a data manager at Aarhus University 
without clinical involvement in the study, and the alloca-
tion tables were stored in a file only accessible by the inde-
pendent data manager. Participants will be randomised 
in a ratio of 1:1. Because of the nature of the interven-
tion, blinding is not possible. The randomisation is strati-
fied by study site (Aarhus, Aalborg, Odense, Randers 
Eligibility screening: RA < 3 months, age ≥ 18, Danish 
speaking, access to Internet, e-Boks and e-mail.
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Usual patient education
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Telephone consultation about 
MTX treatment
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Patient reported outcomes
Follow-up 1, 3, 6, 12 month
Patient reported outcomes
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Fig. 1 Flowchart showing steps from inclusion to data collection
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or Horsens), gender and age (< 69  years/> 70  years). A 
study nurse will perform the randomisation electroni-
cally in REDCap, whereby allocation concealment will be 
ensured. Competitive enrolment will occur to reach the 
target sample size in the enrolment period. Furthermore, 
an estimation of expected participants at each site, based 
on the numbers of patients with RA referred to the hos-
pitals in 2019, was performed.
Interventions
At enrolment, a study nurse briefly repeats informa-
tion on the management of disease flares, infections and 
side effects for all participants. Moreover, a phone call is 
scheduled approximately 3  weeks after MTX initiation 
to ensure proper management of the medicine and to 
support treatment adherence [39]. All participants have 
access to telephone contact with the clinic as usual to 
ensure timely access to care [12].
Table 1 Time schedule and outcomes in the WebRA study
Study period
Enrolment Baseline Follow-up
Time point (month) 0 1 3 6 12
ENROLMENT
Demographic data (gender, age, education, 
employment status) X
Data on diagnosis and laboratory variables: 
Rheumatoid factor (IgM-RF), antibodies to cyclic 
citrullinated peptide (CCP) X
Disease modifying anti-rheumatic drug treatment 
(DMARDs) X X
Disease activity score (DAS28)* X X
Multidimensional health assessment 
questionnaire (0−3; MDHAQ)* X X
Clinical Disease Activity Index (CDAI)* X X
INTERVENTIONS
Web-based patient education
Module 1 (intervention group)
Web-based patient education
Modules 1–3 (intervention group)
Usual patient education (control group)
Telephone consultation (both groups) X
ASSESSMENTS/OUTCOMES
Rheumatoid Arthritis Self-Efficacy Questionnaire 
(RASE-DK)
X X X X X
Patient Knowledge Questionnaire (PKQ-RA-11-
DK)
X X X X X
Compliance Questionnaire for Rheumatology 
(CQR5)
X X X X X
Health Literacy Questionnaire (HLQTM) X X X X X
EuroQol - Quality of Life Questionnaire (EQ-5D-
5L)
X X X X X
Knowledge of MTX (quiz in e-learning program)# X X
Appropriate reaction in case of a flare or 
infection (quiz in e-learning program)#
X X
Healthcare utilisation X
Utilisation of the e-learning program∆ X
* At enrolment, scores for the DAS28, MDHAQ and CDAI are collected from the time of diagnosis, and at follow-up (12 months), scores are collected from a 
consultation in the outpatient clinic scheduled approximately 1 year after diagnosis
# ‘Knowledge of MTX’ and ‘How to react to symptoms and when to contact health professionals’ are quizzes integrated into the e-learning program. Thus, these will be 
administered solely to participants in the intervention group
∆ Data on the use of the e-learning patient education program are collected from the Learning Management System of the e-learning program
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Intervention group: web‑based patient education
In the intervention group, participants will have access 
to the e-learning programme through a link sent to 
them personally by secure mail via e-Boks. They will be 
asked to accomplish module 1 of the programme within 
4  weeks after enrolment and a reminder  will be pro-
cessed 4 days before deadline. The duration of the mod-
ule is approximately 45  min, but users can pause and 
return whenever they want. Participants will be encour-
aged to go through the programme as many times as 
necessary and to involve family and relatives if they like. 
When module 1 is completed, modules 2 and 3 can be 
accessed and the e-learning programme can be used as 
needed throughout the study period.
In module 1, patients complete two tests to examine 
their knowledge of MTX and appropriate actions taken 
by the patient in case of a disease flare or infection. One 
‘stop’ question regarding the dosage of MTX is formu-
lated, and in case of a wrong answer to this specific ques-
tion, the project manager (LRK) will contact the treating 
clinic to ensure contact with the patient (Additional 
file 1).
Control group: usual patient education
In the control group, participants will receive standard 
face-to-face patient education from a nurse in the out-
patient clinic within 4 weeks after enrolment. The dura-
tion of this visit is approximately 1  h, and relatives can 
take part in the conversation. This session will cover the 
following topics: knowledge of RA, the typical disease 
course, prognosis, medication and daily life with RA. The 
nurse will follow a guideline to ensure a certain degree 
of consistency regarding the content of the patient edu-
cation; however, the information will be individually 
adjusted and based on the patients’ needs.
Outcomes
The effect of patient education delivered through e-learn-
ing and usual care in improving patients’ self-manage-
ment of RA will be evaluated via the three following 
aspects: patient-reported outcomes, healthcare utilisa-
tion and utilisation of the e-learning programme. Partici-
pants will respond to questionnaires of patient-reported 
outcomes at baseline and after 1, 3, 6 and 12 months of 
follow-up. The questionnaires will be administered elec-
tronic through REDCap [37, 38], and if not answered, a 
reminder will be processed after 7 and 14 days. Variables 
representing the demographic, clinical, treatment and 
outcome data collected in the study are listed in Table 1.
Primary outcome
The primary outcome is self-efficacy, measured by a dis-
ease-specific Rheumatoid Arthritis Self-Efficacy (RASE) 
questionnaire [40]. The Danish version of RASE showed 
specificity and sensitivity to detect self-efficacy in align-
ment with the original British version [40]. Furthermore, 
RASE has been used as a primary outcome in an RCT 
investigating the impact of different types of outpatient 
care on self-efficacy [41]. RASE covers beliefs about the 
ability to perform tasks related to eight dimensions of 
self-management (relaxation, relationships, function, lei-
sure activities, exercise, sleep, medication, fatigue) [42]. 
The items have five response options (1: strongly disa-
gree, 2: disagree, 3: neither disagree nor agree, 4: agree, 5: 
strongly agree) and a score range of 28–140, with higher 
scores indicating greater self-efficacy [40, 42].
Secondary outcomes
The secondary outcomes are knowledge of RA [43, 44], 
adherence to medication [45], health literacy level [45, 
46] and QoL [46, 47].
Knowledge of RA
Knowledge of RA will be measured by a Patient Knowl-
edge Questionnaire (PKQ) for patients with  RA. This 
questionnaire is based on the original PKQ for RA by Hill 
et al. [43] and the PKQ for early arthritis by Hennel et al. 
[44] which was developed to assess knowledge of RA fol-
lowing patient education. As the original PKQ was devel-
oped before the current management of RA using the 
treat-to-target approach, the target being remission, we 
have updated, translated and adapted the PKQ into Dan-
ish. The adapted and validated Danish version has good 
face validity, reflecting the content of the e-learning pro-
gram, as well as current treatment guidelines and targets. 
The PKQ translation and validation study is in prepara-
tion for publication elsewhere.
The adapted questionnaire consists of 11 multi-choice 
questions covering disease aetiology, signs and symp-
toms, drug therapy and monitoring, joint protection and 
exercise, and energy conversation [44]. In the adapted 
Danish version, each question has one, two or three cor-
rect answers, and inspired by the original version, the 
total score ranges from 0 to 11; higher scores indicate a 
higher level of knowledge [43, 44]. The English versions 
of the instrument has been shown to be reliable and to 
have face validity  [43, 44], and recently, the PKQ was 
used in two studies evaluating multimedia educational 
tools for patients with RA [26, 27].
Adherence to medication
We chose the Compliance Questionnaire for Rheumatol-
ogy (CQR5) as a measure for drug adherence [45]. The 
CQR5 is a reduced version of the original Compliance 
Questionnaire for Rheumatology with 19 items (CQR19) 
[48, 49]. The validation of the CQR5 has been shown to 
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maintain the reliability and validity assessed in CQR19 
while improving the utility in clinical practice by offer-
ing a quicker and easier tool to manage [45]. It consists 
of five questions derived from the original CQR19 cov-
ering reasons to adhere to medications. Answers to each 
question are given on a 4-point Likert scale ranging from 
‘Definitely don’t agree’ (1) to ‘Definitely agree’ (4), with 
lower scores indicating lower levels of adherence [45]. 
A previous factor analysis showed that the CQR5 cor-
rectly predicted group membership measured by the 
full CQR19 for 88.5% of the cases, with a sensitivity to 
predict low adherence of 69% and specificity of predict-
ing high adherence of 97% [45]. The original CQR19 has 
been translated and validated into Danish in connection 
with a study investigating adherence to MTX [50]. Prior 
to the present study, we extracted the five questions cor-
responding to the CQR5 from the Danish CQR19 and 
evaluated the reliability of the Danish CQR5. This reli-
ability study is in preparation.
Health literacy
Health literacy will be measured using the Health Liter-
acy Questionnaire (HLQ™) [51, 52]. The HLQ has nine 
sub-scales covering different aspects of health literacy, 
and each can be used independently [51, 52]. Sub-scales 
2 (‘Having sufficient information to manage my health’), 
4 (‘Social support for health’), 6 (‘Ability to actively engage 
with healthcare providers’) and 9 (‘Understand health 
information well enough to know what to do’) were cho-
sen for this study. Scales 2 and 4 have four response cat-
egories (strongly disagree, disagree, agree and strongly 
agree), and scales 6 and 9 have five response categories 
(cannot do, very difficult, quite difficult, quite easy and 
very easy) [52]. The Danish version has shown strong 
construct and content validity and high composite reli-
ability [52].
QoL
QoL will be measured using the EuroQol (EQ-5D-5L) 
questionnaire [46, 47]. The EQ-5D-5L has the five fol-
lowing dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression [47]. It has the 
five following response categories, which reflect five 
levels of severity: ‘no problems’, ‘slight problems’, ‘moder-
ate problems’, ‘severe problems’ and ‘extreme problems’. 
In addition, respondents rate their overall health for the 
day using a visual analogue scale (VAS) [47]. The instru-
ment has been widely tested and used in both general 
and patient populations, including the population with 
RA [47, 53].
Clinical outcomes
The clinical outcomes of RA will be retrieved from 
patients’ medical records. Based on the ACR/EULAR rec-
ommendations on how to report disease activity in clini-
cal trials, the Disease Activity Score based on the 28-joint 
count (DAS28) and the Clinical Disease Activity Index 
(CDAI) [54] will be used. DAS28 is a composite score 
consisting of the 28-joint count, laboratory variable and 
patient’s assessment of general health on 100  mm VAS 
[55, 56]. Scores range from 0 to 9.4 and disease activity 
is classified as remission, low, moderate or high [56]. The 
CDAI is a simple measure of disease activity of 28 joints 
without laboratory variables, integrating both the physi-
cian and the patient global assessment of disease activity 
[56]. Scores range from 0 to 76.0, and disease activity is 
classified as remission, low, moderate or high [56]. Func-
tional status will be measured by the Multidimensional 
Health Assessment Questionnaire (MDHAQ) [57], which 
comprises 10 items related to activities of daily living. 
Each item has four response categories (without any diffi-
culty, with some difficulty, with much difficulty, unable to 
do). Item scores range from 0 to 3; higher scores indicate 
worse function and greater physical disability [57].
Healthcare utilisation
After completion of the follow-up period, data on the uti-
lisation of healthcare in the study period will be retrieved 
from the medical record. This includes the number of 
contacts with the outpatient clinic, that is, telephone con-
tacts with the rheumatology staff, as well as planned and 
acute visits. The focus for the contact or visit will be cat-
egorised within the following topics: flare, joint injection, 
medical treatment, medical investigations (e.g., bloods, 
magnetic resonance imaging [MRI] or X ray), informa-
tion and guidance related to RA or self-administration of 
medicine.
Utilisation of the e‑learning program
By the end of the study, data on the use of the e-learn-
ing programme will be assessed. This includes the com-
pletion of modules, time spent, the number of logins to 




Self-efficacy was the basis for the sample size estimation. 
An RCT on the effect of internet-based patient educa-
tion through an online self-management program for 
RA among 93 patients found a mean self-efficacy score 
of 84.1 (standard deviation [SD] 16.3) in the intervention 
group receiving online education and 68.6 (SD 23.3) in 
the control group receiving standard patient education 
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[19]. This equals a mean difference of 15.5 (standard 
error [SE]: 4.27). Based on the SE, we calculated the SD 
to 20.1. Based on this previous study, we wish to see at 
least a difference of 10% between the groups [19]. Given 
a statistical power of 90%, p value = 0.05, we will need a 
sample size of 80 patients in each group. To account for 
attrition and loss to follow-up, we intend to recruit 190 
participants.
Statistical analysis
Descriptive statistics will be used to describe and sum-
marise the characteristics of the participants, that is, 
demographic data, disease-specific variables, treatment 
and covariates; the DAS28, MDHAQ and CDAI; and 
the allocation of participants to trial groups. Differences 
between groups for the primary and secondary outcome 
measures from baseline to the 12-month follow-up will 
be evaluated by the chi-square test for dichotomous 
variables and the Kruskal–Wallis test for continuous 
variables.
Differences within and between groups for the primary 
and secondary outcomes will be assessed using repeated 
measures modelling, that is, the one-way analysis of vari-
ance (ANOVA) test, including the F test. An additional 
post hoc test will be done to determine where the differ-
ence is. This will account for time, group and interaction 
effects. To enable intention-to-treat (ITT) analysis, miss-
ing data will be imputed using single imputation, that is, 
replacement of the missing value by the estimated popu-
lation mean or median, depending on the distribution of 
data. In addition to the ITT analysis, a conservative com-
plete case (per protocol [PP]) analysis will be conducted 
to assess the impact of the missing data. The PP analysis 
will be based on evaluation of all participants who com-
pleted the 12-month follow-up. Results from the ITT and 
PP analyses will be compared to assess the efficacy of the 
intervention. All analyses will be adjusted for baseline 
values. Summary statistics will be presented as means 
with standard deviation and 95% confidence interval for 
continuous variables with a normal distribution, num-
bers and percentages for dichotomous categories and 
logarithm transformed data as median with 95% confi-
dence interval. STATA version 16.1 [58] will be used in all 
statistical analyses.
Organisation and patient involvement
A steering group with collaborators from the participat-
ing sites, patient research partners and supervisors has 
been established. The group represents expertise in rheu-
matology, clinical epidemiology, qualitative research and 
the patient perspective. Furthermore, two international 
collaborators with expertise in patient education in 
inflammatory arthritis are involved. To ensure the pro-
gress of the project, the project leader, LRK, will provide 
close follow-up in all phases. Meetings with the steering 
group are planned twice a year and frequently contact 
between the project leader and study nurses will occur 
to ensure the completion of the study by ongoing evalu-
ation and adjustment of procedures. At each participat-
ing site a lead investigator is identified and study nurses 
are affiliated the study, and are responsible for identifica-
tion of eligible participants, recruitment, enrolment and 
data collection. LRK and AdT will also participate in the 
recruitment of participants and data collection. Lead 
investigators will be steering group members. A monthly 
newsletter is send to all sites with up-dates about the 
recruitment rate and data collection.
Two patient research partners are involved in the 
project and have contributed to the development of 
the e-learning program, discussions on the planning 
of the RCT and patient information material. Involv-
ing patient research partners in research projects is 
strongly recommended because they contribute experi-
ential knowledge, and thus, promote research based on 
the needs of patients [59]. The patient research partners 
will also be involved in the discussion of the results and 
dissemination.
Discussion
Patient education and guidance is needed by most 
patients when newly diagnosed because of their disease-
related distress and the uncertainty of living with a new 
long-term condition. Evidence on the effect of web-
based patient education and online modes of delivering 
patient education in RA is lacking; hence, there is a need 
for this study. If the intervention is shown to be effective, 
the intention is to further develop and provide a patient 
education intervention to support self-management 
in patients with RA. We intend to expand on modes of 
delivering patient education by offering different ways of 
learning, accommodating different needs, abilities and 
competences among patients. The target group of the 
present study is newly diagnosed patients; however, we 
expect the programme to be a supportive tool through-
out the course of the disease because it offers a wide 
range of information related to RA, as well as guidance 
and inspiration towards various aspects of life with RA. 
Presumably, not all patients will benefit from web-based 
patient education. Even so, face-to-face patient educa-
tion may be replaced by web-based patient education for 
some and a supplement for others. In addition, it may 
contribute to bridging the gap between the healthcare 
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system and everyday life by being an ongoing accessible 
resource.
We believe there is methodological strength, as the 
effectiveness is being tested in a randomised controlled 
study design, with reduced risk of bias. An equally 
important strength is the study sample size and the 
involvement of several rheumatology clinics represent-
ing a wide group of patients, which will enhance the 
external validity because of recruitment from both uni-
versity and regional hospital referral areas. We expect 
this study to be feasible and acceptable to both partici-
pants and health professionals, as a minimum resource 
from both parts is required.
A limitation of this study could be the risk of intro-
ducing a potential selection bias; this could arise 
because we can only include patients with access to 
the internet. However, in 2019, only 6% of families in 
Denmark lacked internet access [28]. Another concern 
could be patients’ willingness to participate because 
some may reject participation as a result of worries 
about technical issues. This could result in the exclu-
sion of patients with low health literacy. The study 
could also be limited by loss to follow-up and lower 
response rates of the repeated follow-up outcome ques-
tionnaires. However, to accommodate this, we have 
accounted for a 15% dropout rate in the power calcu-
lation, and reminders on questionnaires will be sent 
twice.
After the RCT, the two following additional studies 
will be carried out: (1) a qualitative study exploring the 
patient perspective on web-based patient education and 
(2) an implementation study based on the non-adop-
tion, abandonment, scale-up, spread and sustainability 
(NASSS) framework [60] to prepare this new technol-
ogy for application in daily clinical practice. Overall, we 
expect the results to contribute new insights into the 
area of patient education within RA, and we think that 
the study will be useful to future healthcare organisations 
because it will offer different modes of patient education 
and allow for individual adaptations.
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